Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 6/20 | 0.46 |
| ▸ | FNTB | P49356 | 6/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | PGGT1B | P53609 | 6/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.37 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.37 |
| ▸ | MAT2A | P31153 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5655017 | 0.81 | FNTA (0.38) | FNTAFNTBIDO1PGGT1BKDM4E | |
| SCHEMBL6009561 | 0.81 | FNTA (0.49) | FNTAFNTBIDO1PGGT1B | |
| SCHEMBL5543925 | 0.80 | FNTA (0.60) | FNTAFNTBIDO1PGGT1B | |
| SCHEMBL7087571 | 0.79 | IDO1 (0.40) | FNTAFNTBIDO1PGGT1B | |
| SCHEMBL7090215 | 0.79 | FNTA (0.48) | FNTAFNTBIDO1PGGT1B | |
| SCHEMBL5026990 | 0.77 | CSNK2A2 (0.45) | FNTAFNTBIDO1PGGT1BKDM4E | |
| SCHEMBL16632803 | 0.76 | RORC (0.59) | — | |
| SCHEMBL6010464 | 0.75 | FNTA (0.60) | FNTAFNTBIDO1PGGT1B | |
| SCHEMBL6010160 | 0.75 | FNTA (0.78) | FNTAFNTB | |
| SCHEMBL7093092 | 0.75 | FNTA (0.44) | FNTAFNTBIDO1PGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1322650-B1 | FARNESYL TRANSFERASE INHIBITING 6-HETEROCYCLYLMETHYL QUINOLINE AND QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2008-09-24 | — | — | EP | disclosed |
| US-7196094-B2 | Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-03-27 | — | — | US | disclosed |
| US-20030207887-A1 | Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207887-A1 | Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives | FNTA, FNTB, RCE1 | FNTA 1/4885FNTB 2/4885IDO1 2867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.